Heron Therapeutics is a commercial-stage biotechnology company whose acute care portfolio includes ZYNRELEF, APONVIE, CINVANTI, and SUSTOL. After a court decision adverse to its Cinvanti patents in mid-2026, sell-side price targets were reset sharply lower, and coverage thinned. H.C. Wainwright cut its objective from $4 to $2.00 in June 2026 before moving its rating from Buy to Hold in August 2026, while Needham downgraded the stock to Hold without a price target in June 2026.
As a result, the current, verifiable analyst price target is essentially a single $2.00 objective, and independent aggregators report an average analyst price target near $2.00. The $2.00 figure is used here as the central target because it is the only current, attributable target; earlier Northland Securities ($4) and Jefferies ($5) targets date back to late 2025 and are no longer current. This is a thin and cautious consensus rather than a robust one, so the target should be read as a directional reference, not a forecast.
HRTX closed around $0.37 on November 9, 2026, up roughly 26% in a single session after the company disclosed a definitive agreement to sell substantially all of its assets to CorMedix for $145 million in cash and stock plus up to $55 million in potential earn-out payments. The shares remain near the low end of a 52-week range of about $0.26 to $1.58, with a market capitalization near $70 million.
Moving from $0.37 to $2.00 would require an advance of about 440%, a very large percentage move. Because Heron will retain its roughly $2.3 billion of net operating loss carryforwards, the CorMedix shares it receives, future royalties and earn-outs, and cash on hand, the path to any substantially higher valuation now depends less on product revenue and more on how the board redeploys proceeds into new businesses or assets — an outcome that is inherently difficult to model.
The CorMedix transaction gives Heron a clearer, cash-generating path forward. It converts an uncertain operating business into a balance of cash, equity, and contingent value, while preserving significant tax assets that could shelter future income. Third-quarter results also showed a shrinking loss — $5.0 million versus $17.5 million a year earlier — as gross margins held up despite lower revenue. Any value-creating acquisition, investment, or strategic transaction announced after closing could re-rate the shares substantially, as could favorable developments in patent appeals or royalties on the divested products.
Reaching $2.00 is a demanding objective. Product revenue has been declining, with third-quarter net product sales of $35.3 million down from $38.2 million a year earlier, and the divestiture removes the core operating business. The stock trades below $1, carries a Hold-leaning consensus, and faces genuine uncertainty about what Heron will become after closing. Execution risk on a value-creating redeployment of capital, dilution risk, and the possibility that the retained assets simply trade at a discount to their theoretical worth could keep the shares far below the $2.00 target for an extended period.
HRTX trades well below its 52-week high near $1.58 and just above its 52-week low near $0.26. The $1.00 level represents both a psychological threshold and a meaningful round-number barrier, while the recent session high near $0.42 is an early short-term resistance zone. As a sub-$1 name, the stock also carries the structural overhang of potential Nasdaq listing-compliance considerations, which can influence institutional participation and liquidity.
Analyst price targets generally reflect a roughly 12-month research horizon, though no single firm's horizon is stated here, and the thin coverage makes the $2.00 figure less precise than a typical consensus. Investors should watch for closing of the CorMedix transaction and its terms, any subsequent strategic transaction or capital deployment, the status of patent appeals, quarterly updates on retained royalties and earn-outs, and any renewed analyst coverage or target revisions following the deal.
Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. Traders can use these signals to surface opportunities, track positions, and identify shifting trends more efficiently than manual screening allows. For those following volatile small-cap names such as HRTX, systematic signal tools can add a useful, data-driven layer to their own research.
The $2.00 central target, derived from the current analyst price target, sits roughly 440% above the latest price near $0.37 — a very large move. Support comes from the CorMedix asset sale, retained tax attributes, and a narrowing loss, while the principal obstacles are declining revenue, an asset-light post-deal structure, Hold ratings, and execution uncertainty around redeploying proceeds. With analyst coverage thin and targets recently reset lower, investors should treat $2.00 as a reference point, not a likely near-term outcome, and monitor deal closing and capital-allocation decisions as the key catalysts.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, HRTX has been loosely correlated with FULC. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if HRTX jumps, then FULC could also see price increases.
| Ticker / NAME | Correlation To HRTX | 1D Price Change % | ||
|---|---|---|---|---|
| HRTX | 100% | +0.94% | ||
| FULC - HRTX | 47% Loosely correlated | N/A | ||
| AMRN - HRTX | 44% Loosely correlated | +0.09% | ||
| ABVX - HRTX | 44% Loosely correlated | +3.45% | ||
| SION - HRTX | 41% Loosely correlated | +3.64% | ||
| TENX - HRTX | 40% Loosely correlated | -5.06% | ||
More | ||||